Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Nintendo Share Sale: MUFG and Bank of Kyoto to Sell Stakes in Strategic Unwinding
PBOC Scraps FX Risk Reserves to Curb Rapid Yuan Appreciation
Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates
Germany and China Reaffirm Open Trade and Strategic Partnership in Landmark Beijing Visit
Gold Prices Steady in Asia, Set for Strong February Gains on Safe-Haven Demand
Australian Job Advertisements Hit 16-Month High as Labour Market Stays Resilient
FAA Plans Flight Reductions at Chicago O’Hare as Airlines Ramp Up Summer Schedules
Hyundai Motor Group to Invest $6.26 Billion in AI Data Center, Robotics and Renewable Energy Projects in South Korea
Gold Prices Surge Over 2% After U.S.-Israel Strikes on Iran Spark Safe-Haven Demand
Strait of Hormuz Oil and LNG Shipments Disrupted After U.S.-Israel Strikes on Iran
Boeing Secures $166.8 Million U.S. Navy Contract for P-8A Engineering and Software Support
Middle East Airspace Shutdown Disrupts Global Flights After U.S.-Israel Strikes on Iran
Trump Orders Federal Agencies to Halt Use of Anthropic AI Technology
Nvidia to Launch New AI Inference Processor to Boost OpenAI Performance
Samsung and SK Hynix Shares Hit Record Highs as Nvidia Earnings Boost AI Chip Demand
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade
APEX Tech Acquisition Inc. Raises $111.97 Million in NYSE IPO Under Ticker TRADU 



